Skip to main content
Joincare Pharmaceutical Group Industry Co., Ltd. logo

Joincare Pharmaceutical Group Industry Co., Ltd. — Investor Relations & Filings

Ticker · 600380 ISIN · CNE000001816 LEI · 3003006PUWUKPH72TS46 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 3,000 across all filing types
Latest filing 2026-05-15 Call Transcript
Country CN China
Listing Shanghai Stock Exchange 600380

About Joincare Pharmaceutical Group Industry Co., Ltd.

http://www.joincare.com/

Joincare Pharmaceutical Group Industry Co., Ltd. is a comprehensive healthcare enterprise focused on the research, development, manufacturing, and commercialization of innovative medicines and high-end pharmaceutical products. The company maintains a diverse portfolio spanning respiratory medicine, gastroenterology, endocrinology, cardiovascular health, and medical diagnostics. A significant portion of its operations involves the production of inhaled formulations, biologics, and active pharmaceutical ingredients (APIs). Through its integrated industrial chain and subsidiaries, Joincare emphasizes technological innovation in complex generics and biosimilars. Its strategic focus includes the development of advanced drug delivery systems and the expansion of its presence in global markets, aiming to provide high-quality therapeutic solutions across multiple clinical specialties.

Recent filings

Filing Released Lang Actions
健康元药业集团股份有限公司关于2025年度暨2026年第一季度业绩说明会召开情况的公告
Call Transcript Classification · 80% confidence The document is an official announcement (“公告”) summarizing a 2025 annual and 2026 Q1 performance explanation meeting hosted via video and online text interaction on the Shanghai Stock Exchange. It includes an organized list of investor questions and the company’s detailed responses. Although it is not a formal earnings press release or full financial statements, it is essentially a transcript-style summary of the live Q&A session from an investor-oriented earnings meeting. This fits the definition of a conference call/event transcript rather than a standalone report or simple publication announcement. Therefore, it should be classified as a Call Transcript (CT).
2026-05-15 Chinese
健康元药业集团股份有限公司关于为控股子公司提供担保进展情况的公告
Regulatory Filings
2026-05-08 Chinese
健康元药业集团股份有限公司关于获得药物临床试验批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from a pharmaceutical company about receiving an official approval notice for a clinical trial of a new drug. It details the drug name, clinical trial approval, regulatory body (National Medical Products Administration), and related drug development information. The document is relatively short (1889 characters) and serves as a formal public announcement of the approval rather than a detailed report or financial filing. It does not contain financial statements, management discussion, or regulatory certifications. It is not an annual or interim report, earnings release, or any form of financial or governance report. It is a regulatory announcement about a clinical trial approval, which fits best under the category of Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2026-05-06 Chinese
健康元药业集团股份有限公司2025年度独立董事述职报告（彭娟）
Board/Management Information Classification · 95% confidence The document is titled '2025年度独立董事述职报告' which translates to '2025 Annual Independent Director's Work Report'. It is a detailed report by an independent director on their duties, attendance, and activities during the year 2025. The content includes descriptions of board meetings, committee participation, audit oversight, governance, and other director responsibilities. It is not a financial report like an annual or interim report, nor is it an announcement or certification. It is a management-related report focusing on board and director activities and governance. Therefore, the most appropriate classification is 'Board/Management Information' (MANG). The document length is 4470 characters, which is sufficient for a substantive report rather than a brief announcement.
2026-03-31 Chinese
健康元药业集团股份有限公司2025年度募集资金存放、管理与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is titled '2025 年度募集资金存放、管理与实际使用情况专项报告' which translates to '2025 Annual Report on the Storage, Management and Actual Use of Raised Funds'. It details the company's fundraising activities, including domestic and overseas fundraising projects, the amounts raised, usage of funds, changes in investment projects, and compliance with regulatory requirements. It references approvals from the China Securities Regulatory Commission and includes detailed tables on fundraising amounts, usage, and changes. The document is comprehensive, about 15,000 characters long, and contains substantive financial data and analysis related to fundraising and capital management. This fits the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes. It is not an announcement of a report publication, nor a general regulatory filing. Therefore, the appropriate classification is CAP with high confidence.
2026-03-31 Chinese
健康元药业集团股份有限公司2025年年度报告（英文版）
Annual Report Classification · 100% confidence The document is titled 'Annual Report 2025' for Joincare Pharmaceutical Group, indicating it is a comprehensive yearly report. It includes a letter to shareholders, detailed sections such as Management Discussion and Analysis, Corporate Governance, Financial Statements, and an audit report by Grant Thornton. The presence of audited financial statements, detailed business and financial analysis, risk disclosures, and a profit distribution plan confirms this is a full annual report. The document length is substantial (15,000 characters), and it contains substantive financial data and analysis, not just an announcement or summary. Therefore, it fits the definition of an Annual Report (10-K).
2026-03-31 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.